Retatrutide dosing & administration
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
2 mg
Frequency
Once weekly
Duration
Weeks 1-4 (then escalate 2 mg every 4 weeks)
Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
4-8 mg
Frequency
Once weekly
Duration
Maintenance after titration
12 mg
Frequency
Once weekly
Duration
Maintenance (highest studied)
Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Timing
Best time to take
Pick any consistent day each week—what matters most is doing it the same day each week. Many people choose weekend mornings so any initial nausea happens when they can rest.
With food?
Inject regardless of food timing. However, eating slowly and avoiding large, fatty meals helps minimize nausea. Many users find eating smaller, more frequent meals works better on this medication.
If stacking
Do not combine with other GLP-1 agonists like semaglutide or tirzepatide—retatrutide already hits all three receptors [2]. Metformin is safe and often beneficial to continue [6].
Adjusting your dose
Increase if
- You've been on current dose for 4+ weeks with good tolerance
- Weight loss has plateaued and you're below target
- GI side effects have resolved or become minimal
- Your healthcare provider recommends escalation
Decrease if
- Nausea or vomiting is persistent and interfering with daily life
- You're losing weight too rapidly (more than 3 lbs/week consistently)
- GI side effects don't improve after 2-3 weeks on current dose
- You experience hypoglycemia symptoms
Signs of right dose
- Steady weight loss of 1-2 lbs per week
- Reduced appetite without severe nausea
- Improved energy levels
- Blood sugar levels stabilizing (if diabetic)
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin)—the same easy technique used for insulin
Best sites
Storage
Before reconstitution
Keep retatrutide refrigerated at 36-46°F (2-8°C). Protect from light by keeping in original packaging. Never freeze the medication. Can tolerate brief periods at room temperature (up to 86°F/30°C) for transport.
After reconstitution
Once prepared for use, store refrigerated at 36-46°F (2-8°C). Do not freeze reconstituted solution. Keep away from direct light. Use within 28 days of first use.
Signs of degradation — discard the vial
Sample daily schedule
Same day each week (e.g., Saturday morning)
As prescribed: 1-12 mg based on titration phase injection
Site: Rotate between abdomen, thigh, and arm weekly
Once-weekly dosing. Pick a day you'll remember consistently. If you miss a dose, take it within 4 days of the missed dose. If more than 4 days have passed, skip that week and resume on your normal schedule.
Safety
Is it safe?
Side effects
Commonly reported: Nausea, Diarrhea, Constipation, Decreased appetite
Less common: Increased heart rate, Injection site reactions
Stop and seek help if
- Severe or persistent abdominal pain (possible pancreatitis)—seek emergency care
- Signs of allergic reaction: rash, swelling, difficulty breathing
- Persistent severe nausea or vomiting that doesn't improve with dose reduction
- Symptoms of gallbladder problems (right upper abdominal pain)
- Symptoms of severe hypoglycemia that recur despite medication adjustments
- Any concerning mental health changes
Retatrutide is an investigational medication currently in clinical trials. It is not FDA approved. Any use should be under the supervision of a qualified healthcare provider. Never start, stop, or change your dose without medical guidance.
Flagged pairings
- Semaglutide — Do NOT combine. Both target the GLP-1 receptor—using them together provides no additional benefit and increases side effects.
- Tirzepatide — Do NOT combine. Retatrutide already hits both GIP and GLP-1 receptors that tirzepatide targets, plus glucagon.
- Insulin — High interaction risk. Retatrutide dramatically lowers blood sugar—insulin doses typically need significant reduction (20-50%) to prevent hypoglycemia.
- Sulfonylureas (glipizide, glyburide) — Increased hypoglycemia risk. These drugs also stimulate insulin release. Dose reduction usually needed.
Published research
What the studies show
Jastreboff AM, Kaplan LM, Frías JP et al. · 2023
In 338 adults with obesity, retatrutide produced dose-dependent weight loss up to 24.2% at 48 weeks with the 12mg dose—the highest ever recorded for any anti-obesity medication in a Phase 2 trial. Even the lowest dose (1mg) outperformed placebo.
Kaur M, Misra S · 2024
This comprehensive review confirmed retatrutide's unique triple-receptor mechanism offers advantages over single or dual agonists. The glucagon receptor activation may contribute additional energy expenditure and fat burning not seen with GLP-1-only drugs.
Tewari J, Qidwai KA, Tewari A et al. · 2025
Pooled analysis of all available trials confirmed retatrutide shows a clear dose-response relationship for weight loss. The safety profile was comparable to placebo for serious adverse events, with GI symptoms being the main tolerability concern.
Coskun T, Wu Q, Schloot NC et al. · 2025
Detailed body composition analysis showed retatrutide users lost primarily fat mass while preserving lean muscle mass better than typically seen with dieting alone—crucial for long-term metabolic health.
Goldney J, Hamza M, Surti F · 2025
This review placed retatrutide in context of the obesity medication landscape, noting its triple mechanism represents a new frontier in metabolic pharmacotherapy with potential to address multiple aspects of metabolic disease simultaneously.
Rosenstock J, Frias J, Jastreboff AM et al. · 2023
In 281 adults with type 2 diabetes treated with diet and exercise alone or a stable dose of metformin, retatrutide reduced HbA1c by up to 2.02% at 24 weeks and body weight by up to 16.94% at 36 weeks. Mild-to-moderate GI adverse events occurred in 35% of retatrutide-treated participants, with no reports of severe hypoglycemia.
Sanyal AJ, Kaplan LM, Frias JP et al. · 2024
In a 98-participant substudy of adults with MASLD and at least 10% liver fat, retatrutide reduced liver fat by 81.4% (8 mg) and 82.4% (12 mg) relative to baseline at 24 weeks versus a 0.3% increase with placebo. Most participants on the two highest doses reached normal liver fat (under 5%) by 24 weeks.
Sodhi M, Rezaeianzadeh R, Kezouh A et al. · 2023
In a cohort study of patients using GLP-1 receptor agonists (liraglutide or semaglutide) for weight loss, GLP-1 agonist use was associated with increased risk of pancreatitis (adjusted hazard ratio 9.1), bowel obstruction (4.2), and gastroparesis (3.7) compared with bupropion-naltrexone users.
Liddle RA, Goldstein RB, Saxton J · 1989
Among 51 obese subjects on an 8-week very-low-calorie diet, 25.5% developed gallstones on ultrasound versus none in the non-dieting comparison group, and three required gallbladder removal—establishing rapid weight loss as a risk factor for gallstone formation.
Jastreboff AM, Aronne LJ, Ahmad NN et al. · 2022
In the SURMOUNT-1 trial of 2,539 adults with obesity, tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo, and 57% of participants on the highest dose lost at least 20% of body weight.
Giblin K, Kaplan LM, Somers VK et al. · 2025
Describes the TRIUMPH program: four Phase 3, multicenter, randomized, double-blind registrational trials of once-weekly retatrutide enrolling more than 5,800 participants with obesity and related conditions, confirming retatrutide is in active Phase 3 development.
Wilding JPH, Batterham RL, Davies M et al. · 2022
One year after stopping semaglutide 2.4 mg and lifestyle intervention, participants had regained two-thirds of the weight they lost during treatment (11.6 of 17.3 percentage points), and cardiometabolic improvements reverted toward baseline.
Bjerre Knudsen L, Madsen LW, Andersen S et al. · 2010
GLP-1 receptor agonists caused calcitonin release, C-cell proliferation, and C-cell tumors in rodents, but thyroid C-cells in humans and monkeys have low GLP-1 receptor expression, monkeys showed no calcitonin response to prolonged treatment, and calcitonin levels in patients on liraglutide for 2 years remained at the lower end of the normal range.
Wilding JPH, Batterham RL, Calanna S et al. · 2021
In the STEP 1 trial of 1,961 adults with overweight or obesity, once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo.
Head to head
Retatrutide compared
Want the full picture?
The complete Retatrutide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.